Table 2 Non-haematological toxicity and second primary malignancy in relapsed/refractory multiple myeloma.
Daratumumab-containing treatment (n/N, %) | Control treatment (n/N, %) | |
|---|---|---|
All grade peripheral neuropathy | ||
CANDOR study | 53/308 (17%) | 13/153 (8%) |
CASTOR study | 115/243 (47%) | 89/237 (37%) |
Substudy of CASTOR study | ||
Standard cytogenetic risk MM | 67/137 (49%) | 50/136 (37%) |
High cytogenetic risk MM | 22/40 (55%) | 13/34 (38%) |
Grade 3–4 peripheral neuropathy | ||
CANDOR study | 0/308 (0%) | 0/153 (0%) |
CASTOR study | 11/243 (4.5%) | 16/237 (6.8%) |
Substudy of CASTOR study | ||
Standard cytogenetic risk MM | 4/137 (2.9%) | 8/136 (5.9%) |
High cytogenetic risk MM | 2/40 (5.0%) | 4/34 (12%) |
All grade hypertension | ||
Substudy of CASTOR study | ||
Standard cytogenetic risk MM | 15/137 (11%) | 5/136 (3.7%) |
High cytogenetic risk MM | 4/40 (10%) | 1/34 (2.9%) |
Substudy of POLLUX study | ||
Standard cytogenetic risk MM | 12/192 (6.3%) | 8/176 (4.5%) |
High cytogenetic risk MM | 9/35 (25.7%) | 2/34 (5.9%) |
Grade 3–4 hypertension | ||
Substudy of CASTOR study | ||
Standard cytogenetic risk MM | 9/137 (6.6%) | 1/136 (0.7%) |
High cytogenetic risk MM | 2/40 (5%) | 0/34 (0%) |
Substudy of POLLUX study | ||
Standard cytogenetic risk MM | 5/192 (2.6%) | 2/176 (1.1%) |
High cytogenetic risk MM | 4/35 (11.4%) | 0/34 (0%) |
Acute cardiac failure | ||
CANDOR study | 23/308 (7.5%) | 16/153 (10%) |
Ischemic heart disease | ||
CANDOR study | 13/308 (4.2%) | 5/153 (3.3%) |
Acute renal failure | ||
CANDOR study | 18/308 (5.8%) | 12/153 (7.8%) |
Second primary malignancy | ||
POLLUX study | 8/286 (2.8%) | 10/283 (3.6%) |
CASTOR study | 6/243 (2.5%) | 1/237 (0.4%) |
